Particularly, IFNα-2b, a highly potent cytokine that belongs to the IFNα family, was shown to exert the antiproliferative activity (predominantly via the JAK-STAT pathway), and was approved by The Food and Drug Administration (FDA) for treatment of renal cell cancer, malignant melanoma and hairy cell leukemia [10,11]. The gene discussed is IFNA2; the disease is renal cell adenocarcinoma.